Skip to main content
Smart Investors Daily
RA

NASDAQ · RAPP

Rapport Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$23.16

Down-$0.43 (-1.82%)

Updated Nov 21, 2026, 7:58 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.05B
P/E ratio
-111.89
Dividend yield
0.00%
52-week range
$22.06 – $52.93
Volume
437.72K
Avg. volume
522.83K

Price performance · RAPP

RAPP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

RAPP closed at $23.16 after 21 trading sessions, down 10.68% for the selected period.

Last close
$23.16
Period change
-10.68%
Period low
$22.50
Period high
$27.54
Daily close
View OHLC price history
RAPP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$23.23$23.83$23.00$23.16437.72K
Nov 19, 2026$23.47$24.17$23.34$23.59301.04K
Nov 18, 2026$23.70$25.17$22.91$23.40731.32K
Nov 17, 2026$24.66$24.92$23.41$23.76526.32K
Nov 16, 2026$25.78$26.14$24.625$24.82462.82K
Nov 13, 2026$25.85$26.29$25.11$26.15316.12K
Nov 12, 2026$26.76$26.90$25.445$25.85568.43K
Nov 11, 2026$26.06$27.10$25.7698$27.02631.81K
Nov 10, 2026$25.83$26.90$25.3001$25.96660.15K
Nov 9, 2026$24.50$26.345$24.06$26.07789.4K
Nov 6, 2026$23.72$24.53$22.95$24.44866.48K
Nov 5, 2026$25.64$25.665$23.67$23.72706.97K
Nov 4, 2026$26.12$26.36$25.27$25.93956.87K
Nov 3, 2026$25.39$26.06$25.13$25.44823.48K
Nov 2, 2026$25.16$26.16$24.22$25.131.33M
Oct 30, 2026$23.94$25.43$23.86$25.05926.56K
Oct 29, 2026$22.58$25.755$22.5143$24.213.1M
Oct 28, 2026$22.55$23.94$22.061$22.505.96M
Oct 27, 2026$25.11$28.31$25.11$27.54703.93K
Oct 26, 2026$26.02$27.9499$25.08$25.331.04M
Oct 23, 2026$27.54$27.756$25.705$25.931.19M

Latest RAPP news

The latest Smart Investors Daily articles mentioning RAPP.

RAPP research

Overview

Company profile and research snapshot.

Company profile

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.00
Implied upside
—
Analysts
—
RAPP recent ratings
DateFirmRatingTarget
Nov 5, 2026UBSBuy—
Nov 5, 2026Wells FargoOverweight—
Nov 5, 2026GuggenheimBuy—
Oct 21, 2026Jones TradingBuy—
Oct 21, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Buy the Dip: 5 Stocks Insiders Are Loading Up On After the Recent Market Sell-Off

Thursday, November 5 represented the worst trading session for the U.S. market in over a year. the Nasdaq Composite dropped 5.52%, the S&P 500 fell 4.36%, and the Dow shed 3.44%, as Wall Street’s post-midterm optimism could not last long. Concerns around a potential weakness in AI spending reversed the post-election rally and led to […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.